We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
-12.67%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$167M
AUM Growth
-$14.7M
(-8.1%)
Cap. Flow
+$17.1M
Cap. Flow
% of AUM
10.22%
Top 10 Holdings %
Top 10 Hldgs %
63.99%
Holding
56
New
13
Increased
16
Reduced
7
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oscar Health
OSCR
|
+$9.25M |
| 2 |
Prothena Corp
PRTA
|
+$6.53M |
| 3 |
Charles River Laboratories
CRL
|
+$6.01M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$5.93M |
| 5 |
Encompass Health
EHC
|
+$5.87M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$7.14M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$4.53M |
| 3 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
+$3.93M |
| 4 |
MeiraGTx Holdings
MGTX
|
+$3.84M |
| 5 |
Humana
HUM
|
+$3.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.99% |
| 2 | Financials | 1.14% |
| 3 | Industrials | 0.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACCD
26
DELISTED
Accolade Inc
ACCD
| $1.32M | 0.79% |
50,000
-47,988
| -49% | -$1.57M |
|
27
CRISPR Therapeutics
CRSP
$4.58B
| $1.32M | 0.79% |
+17,364
| New | +$1.52M |
|
|
28
Iovance Biotherapeutics
IOVA
$2.23B
| $1.31M | 0.79% |
68,800
-205,961
| -75% | -$4.53M |
|
|
SIOX
29
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $1.03M | 0.62% |
802,180
+308,972
| +63% | +$548K |
|
30
Moderna
MRNA
$21.5B
| $940K | 0.56% |
+3,700
| New | +$1.08M |
|
31
PUT
West Pharmaceutical
WST
$23.1B
| $704K | 0.42% |
+1,500
| New | +$646K |
|
|
CBAY
32
DELISTED
Cymabay Therapeutics
CBAY
| $564K | 0.34% |
+166,775
| New | +$633K |
|
33
Procept Biorobotics
PRCT
$950M
| $500K | 0.3% |
+20,000
| New | +$740K |
|
34
Exicure
XCUR
$11.2M
| $490K | 0.29% |
16,177
-17,990
| -53% | -$2.09M |
|
|
ODT
35
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $404K | 0.24% |
+298,900
| New | +$707K |
|
36
ARS Pharmaceuticals
SPRY
$590M
| $358K | 0.21% |
+53,815
| New | +$437K |
|
37
AbbVie
ABBV
$458B
| – | – |
-24,800
| Closed | -$2.67M |
|
38
Alector
ALEC
$164M
| – | – |
-27,378
| Closed | -$625K |
|
|
AMED
39
DELISTED
Amedisys
AMED
| – | – |
-20,000
| Closed | -$2.98M |
|
40
Assembly Biosciences
ASMB
$506M
| – | – |
-22,136
| Closed | -$924K |
|
|
CLLS
41
Cellectis
CLLS
$286M
| – | – |
-87,103
| Closed | -$1.1M |
|
42
Haemonetics
HAE
$3.58B
| – | – |
-38,319
| Closed | -$2.71M |
|
|
43
Humana
HUM
$46.7B
| – | – |
-9,000
| Closed | -$3.5M |
|
|
44
CALL
Iovance Biotherapeutics
IOVA
$2.23B
| – | – |
-100,000
| Closed | -$2.47M |
|
45
iRhythm Holdings
IRTC
$3.59B
| – | – |
-37,396
| Closed | -$2.19M |
|
46
Lifestance Health
LFST
$4.16B
| – | – |
-38,774
| Closed | -$562K |
|
47
MiMedx Group
MDXG
$626M
| – | – |
-44,225
| Closed | -$268K |
|
|
48
MeiraGTx Holdings
MGTX
$1.09B
| – | – |
-291,080
| Closed | -$3.84M |
|
49
Organogenesis Holdings
ORGO
$308M
| – | – |
-38,000
| Closed | -$541K |
|
50
UnitedHealth
UNH
$382B
| – | – |
-3,300
| Closed | -$1.29M |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q4 2021 Portfolio in Review
As of Q4 2021, Prosight Management held 56 positions worth $167M, down 8.1% from $182M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Prosight Management deployed $17.1M of net new capital in Q4 2021, opening 13 new positions and adding to 16 existing holdings. Its largest new stake was Charles River Laboratories: 15,481 shares worth $5.83M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 91% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Arena Pharmaceuticals Inc, an estimated $7.14M trimmed.
- Prosight Management's largest Q4 2021 buy was Charles River Laboratories: 15,481 shares worth $5.83M.
- Prosight Management added most to Oscar Health in Q4 2021, an estimated $9.25M increase.
- Prosight Management's biggest Q4 2021 reduction was Arena Pharmaceuticals Inc, cutting an estimated $7.14M.
- Prosight Management fully exited Metacrine, Inc. Common Stock in Q4 2021, selling an estimated $3.93M.
- Prosight Management's ten largest holdings make up 64% of its $167M portfolio in Q4 2021.
- Prosight Management opened 13 new positions and closed 20 in Q4 2021.
- Prosight Management's portfolio value fell 8.1% quarter-over-quarter to $167M.
Based on Prosight Management's 13F filing for Q4 2021, filed 14 Feb 2022.